|
| |
Overview
Financial Highlight
Headlines
Business Background UCrest Bhd is a technology provider company which engages in network design, product development, and software development. The firm provides a solution for broadband, wireless and networking products, and services. The company provides technical services to customers such as Telco, ISP, broadband operators, hotel operators, property developers, enterprises and wireless hotspot operators. The groups are engaged in projects related to networks, security systems, and the Internet of Things (IoT) Cloud software application areas. Majority of the revenue comes from the sale of the Internet of Things (IoT) Cloud hardware platform. The company makes its major revenue from Sales of Goods segment and has operations in Russia, Malaysia, and Singapore.
  joyvest Loss making co trying to revive the situation desperately. Your ignorance is bigger than your loss of fortune... 17/04/2021 6:25 AM  fengpinglangjin There are many glove companies in bursa totalling 100b market caps producing for whole world. There is only 1 oem contractor manager vaccine company in bursa producing for whole world and sell direct to vaccine owner. All big and small fund are already parking their fund here. Super rose 12 x from 30 mil to billion profit. Ucrest will rise the same way and more than that becoz its starting caps is small. From 160 m to 10 billion market caps. Dun underestimate russian fund . 17/04/2021 7:04 AM fengpinglangjin From the live stream of 150 ppl..there is really low public interest in this company. When all sifu start buy call when this stock above rm1 when things is confirmed. U will c ucrest on no.1 trending on i3 like last year supermax. 17/04/2021 7:59 AM  Alfonso Sure, Ucrest will soon becoming the no1 hot trending. All looking down on this penny stock at the moment including expert shifus in the market, soon it will left penny as well. Why dont buy now? 17/04/2021 8:10 AM Alfonso Let u have the taste of limit up, nice delicious and unbelievable. All bluechip stocks i have invested most in my portfolio like CIMB, Genting, tenaga also cant fight with this little unpolished gem. 17/04/2021 8:12 AM fms016 I believe stock will always increase in this month but cannot reach LU..maybe trader don't want this stock price increase too high because they want to play intraday..1 day 1-3 cents increase already good.. 17/04/2021 8:34 AM chief999 Mr Feng, now im in dilemma.. Do i allocate somemore from keyasic to ucrest? Im thinking of doing so.. Coz on chart ucrest has bigger potential... 17/04/2021 8:40 AM kytan My view is Ucrest is better than keyasic, keyasic is like a IT support on Ucrest. Major beneficiary is Ucrest. 17/04/2021 9:29 AM Powerplay666 chief 999.. If you are riding on the vaccine play then Ucrest is the 100 % bet. Keyasic is involved in chip design and the md said that the company was not involved in any part of the contract manufacturing for the Russian vaccine. Ucrest has other gems like the i medic etc but the x5 to 10 times share price growth you will witness in the next 3 months will be mostly because of its mega vaccine deal. 17/04/2021 9:35 AM fengpinglangjin Ucrest stock is more or less cornered. Every tickets now is precious. Keyasic still not time but will rise as well due to spillover effect as too much fund interest in ucrest. Probably higher ratio to ucrest is better choicenow. Hold key as well for another possible turn of event albeit smaller ratio. Mth end profit result for key and will spark rally for keyasic jus like the initial stage of ucrest. So probably a multiyr reversal as well for key. Dun forget, Mr Eg said keyasic is not involved in vaccine for NOW. If theres anything down the road he will make neccessary annoucement. So doesnt rule out future involvement. For the vaccine new ventures. Theres 4 pt to note. Pt 1 is oem managment profit. 100m to 1bil x rm1 to rm 4 profit margin. Pt 2 Sputnik efficacy track and trace service for many yrs to come.how many years? May be forever need monitor. Imedic huge penetration and permanent overhaul to revenue base. Millions user on imedic will make more n more healthcare join and adopt the imedic system. Snowball rolling effect will create millions of profit. These part will allow keyasic huge involvement. Billion user on imedic require billion chips and sd card and dongers. Huge investmrnt in technology upgrade and service is needed. Vaccine and technology works hand in hand. Pt 3. Future covid treatment drugs oem management for rdif. Another billion profit on track. This one comeout...crazy movement again. Pt 4. Other vaccine manufactuer had approached ucrest to distribute their vaccine. Ucrest doesnt rule out become own distributors if they on firm note on oem manufacturing management. So for now kiv. 17/04/2021 10:17 AM  probability Sputnik V's approval came as India overtook Brazil to become the country with the second-highest number of cases globally. https://www.bbc.com/news/world-asia-india-55748124 17/04/2021 3:32 PM Ohseng @fengpinglangjing . i missed out the investor briefing , Sad !. just would like to confirm that The profit margin of rm1 - rm4 as oem managment was mentioned in the briefing ? if yes, really very good news and huat ar. 17/04/2021 4:54 PM Ohseng South Korean consortium to produce 100 million doses of Russia's Sputnik V vaccine per month . that means ard 1.2b per year . and noticed South Korea's Huons Global that it will lead a consortium to produce the spuntik vaccin share price up in the 16 morning ard 29.8% but close up 16% on 16 apr 17/04/2021 5:02 PM fengpinglangjin Yes.its stated in briefing. Thats an estimate only. But believe rm 1 to 4 per dose over a rm120 priced vaccine is pretty reasonable. 17/04/2021 5:06 PM Ohseng from the article , Huons estimated manufacturing of the said vaccin is quite huge which is ard 1.2b per year. Does ucrest also included in the supervising and managing south korea and india manufacturing ? 17/04/2021 5:14 PM Ohseng Russia has signed several major vaccine production deals with Indian manufacturers, and India is expected to become a hub for production of the shot. This is expected to begin in May. https://www.reuters.com/business/healthcare-pharmaceuticals/india-receive-sputnik-v-vaccine-doses-this-month-tass-cites-ambassador-2021-04-15/ 17/04/2021 5:15 PM Ohseng a bit disappointed when noticed that south korea 's huons only up 16% on 16 apr after announced the news. is probably the manufacturer profit margin lower than the co that identify and manage contract manufacturer. 17/04/2021 5:20 PM kytan Russia try to have more vaccine. RDIF looking more partner to do it. Current vaccine in the world is too less to cover 80% of popolation. And only rich, selfish countries can have it. 17/04/2021 5:24 PM Ohseng India: Apart from partnership with Dr Reddy’s Labs that is conducting Sputnik V clinical trials locally, and have the distribution rights for the Russian vaccine, RDIF has entered manufacturing partnership with five other local companies for production https://www.hindustantimes.com/india-news/india-may-begin-sputnik-vaccine-import-by-may-start-production-around-july-101618461897427.html 17/04/2021 5:26 PM Powerplay666 During the live zoom, the md mentioned that the contract manufacturing facilities for ucrest will be in China, India and one other country I can't recall. He said China is the fastest to set up and will be ready in 2 months and ship out 2 weeks after. So we estimate the first shipment of vaccine should be earliest in end June. 17/04/2021 5:37 PM Ohseng from the articles related to spuntik v in india and south korea, seem like india n south korea already have their own manufacturers. very high chance ucrest is not involved in it. correct me if i m wrongly read. 17/04/2021 5:38 PM Powerplay666 Ohseng, the Russians have appointed a few oem manufacturers, Korea (huon global) being one of them and Ucrest is the other. Each one of them given around 1 b doses a year to manufacture. Still won't be enough to cover the global shortfall of vaccine but a good problem to have for ucrest. 17/04/2021 5:43 PM Ohseng powerplay666, if contract manufacturing facilities for ucrest also in india then very good. but logically think if they already has their local manufacturers. why still need contract manufacturer . Probably need ucrest imedic ? 17/04/2021 5:51 PM Powerplay666 Ohseng.. It's all about the relationship. Russia has a long term relationship with Ucrest for the last 12 years. In fact over 90 %of Ucrest revenue is derived from Russia. Mr Eg mentioned in the zoom that they personally deal with Putin's no 2 man directly with photo to prove. Which is why the Russians entrusted ucrest with setting up few contract manufacturing facilities in China and India too. 17/04/2021 6:20 PM fengpinglangjin The mou had ddfine the responsibility clearly. Ucrest jus need worry manage the manufacturer and get the production out to rdif. As long as ucrest can produce the 1billion dose.rdif will eat. Whether india ,sk or other manufacturer production how much is not of ucrest concern. Remeber the risk of the mou stated is the risk of not gtting the capacity required. Ucrest had no risk on sales side. 17/04/2021 6:38 PM fengpinglangjin Russia now adopts a mass flood market strategy and aims to grab largest market share by having the vaccine produced and ready for market as soon as possible. Now the world problem is not enuff low risk minimal side effect vaccine. Qty is of utmost importance now. 17/04/2021 6:41 PM Ohseng powerplay666, agree with ur view ( it's all about the relationship) South korea's houns global is a company specialized in the provision of pharmaceutical products. if it also playing the same role as ucrest ( as oem with higher production volume) looks fit to them as they should be more familiar to this industry. moreover it lead a consortium to produce the said vaccine by themself. Is that advisable to take this co share price movement ( listed in south korea) as guideline ??? Hopefully it share price keep on moving higher 17/04/2021 7:57 PM Ohseng just aware of that Ucrest only signed MOU with RDIF. MOU is non binding and legally no enforceable and is only an agreement to agree. Have experienced some cos published MOU and share price going up . but later nothing was materialised. need to monitor closely . Hope everything goes smooth then huat !!! 17/04/2021 8:15 PM Powerplay666 Mr Eg addressed the fact that the mou is actually a definitive agreement because there is already agreement and actions undertaken as he spoke. So the wording should not be taken as non binding 17/04/2021 8:25 PM Powerplay666 In their fb page they described it as having signed a strategic deal with RDIF not mou 17/04/2021 8:37 PM Powerplay666 Monies have already been made by RDIF to setting up the contract manufacturing facilities and technology transfer in China and India on behalf of Ucrest. The great thing about this deal is that Ucrest doesn't cough up even a penny for this. RDIF hands the total responsibility of oem product to Ucrest and pays for the investment at the same time 17/04/2021 8:40 PM kytan To have latest info, whatsapp this number that share on FB investor briefing for first hand info 0194009336. Ask for whatsapp and telegram group. So not need guessing here 17/04/2021 9:15 PM kytan UCREST UPDATE (16 APRIL 2021) ————— TLDR UCREST's strong buying interests on 14 April 2021 intrigued us. Below is the sharing of our best attempt to understand the evolving global COVID-19 vaccine situation, how UCREST fits into the big picture, and what's potentially coming for UCREST, based on their recent MOU and additional elaboration on MOU. ❗️Note: MOU may or may not materialise. ————— DISCLAIMER Information is compiled from publicly available resources. Also, we are merely attempting to connect the dots, not predicting the future. Our understanding could be inaccurate. Valuation of UCREST stock is beyond scope. There is no BUY/SELL recommendation. Investors own their investment decisions and outcomes. ————— This is Part I. Part II here. ————— 1) VACCINE SHORTAGE IS AN ISSUE THAT VARIOUS COUNTRIES AIM TO RESOLVE, BEFORE IT HAPPENS. Until 12 April 2021, only 773 million jabs of COVID-19 vaccines had been administered across the world - just a little more than 2 per cent of the world’s adult population. The world will manufacture 9.5 billion doses by the end of 2021, but it needs more than 14 billion doses as soon as possible to vaccinate the entire adult population. This is almost 3x the number of vaccines the world was producing in the pre-pandemic period for other diseases. 2) FOUR KEY NAMES: RUSSIA, GAMALEYA, SPUTNIK V, RDIF. - Russia has an institution, called Gamaleya (Gamaleya National Research Institute of Epidemiology and Microbiology). - Gamaleya develops Sputnik V, a COVID-19 vaccine. - Sputnik V has an efficacy rate of 91.6%. Can be stored in conventional refrigerators. - RDIF (Russian Direct Investment Fund) funds Gameleya's Sputnik V development. RDIF is also responsible for the vaccine mass deployment. Approved in 59 countries. Most recent: India approved Sputnik V for emergency use. 3) BOTTLENECKS THEY POTENTIALLY FACE: CONTRACT MANUFACTURING APPROVALS. Interestingly, to achieve mass development of Sputnik V, RDIF needs to work together with Asian's vaccine contract manufacturers. However, due to vaccine shortage across a rising number of countries, complex vaccine-politics and nation-protectionism situations could surface. This makes securing overseas contract manufacturers of vaccine a challenge. This means, RDIF requires external support that's not limited by political complexities to mass manufacture Sputnik V vaccine. UCREST is trying to fill exactly this gap. 4) UCREST COMES TO THE RESCUE. 9 April 2021 UCREST announcement: Partnering with RDIF, UCREST navigates political complexities and manages the vaccine contract manufacturers across Asia to achieve Sputnik V mass manufacture. This effort aims to produce at least 100 million doses (and maybe up to 1 billion doses) in 2021 an similarly in 2022. 2023 - depending on actual situation. 100 million doses/year = 100,000,000 doses/year. 1 billion doses/year = 1,000,000,000 doses/year. ————— Part II here. 17/04/2021 9:18 PM kytan This is Part II. Part I here. ————— 5) TARGETED FLOW OF VACCINE MASS DEPLOYMENT. > Gamaleya develops the vaccine formula, then > UCREST liaises with Asian vaccine contract manufacturers to produce Sputnik V vaccine and sells full amounts to RIDF (take-or-pay basis), then > RIDF distributes Sputnik V to Russia and other countries 6) TAKE-OR-PAY BASIS - GUARANTEED REVENUE? The partnership deal signed between UCREST and RDIF is with take-or-pay basis. This means that all amounts manufactured by UCREST (via Asian contract manufacturing) will be fully paid by RDIF, no matter they actually require those amounts of vaccines or not. This is probably because RDIF foresees potential vaccine shortage, and would rather have excess (instead of shortage) of vaccines. 7) AS OF 14 APRIL 2021, IS THIS DEAL CONFIRMED? No. However, management stated the definitive agreement will be signed once the detailed arrangements are finalized. 8) ANY COST & RISK INVOLVED? From UCREST management, there is no capital expense or investment required (Their core strategy is to add value by navigating political complexities to enable mass manufacturing Sputnik V). Risks: Currency exchange risk and production risk (insufficient contract manufacturing capacity that may refrain UCREST from fulfilling the minimum requirement in a timely manner), payment delay(s) by RDIF. 8) WHY UCREST? According to management, - UCREST has well-established medical technology operations in China, Taiwan and Singapore. - They have been actively engaged in various healthcare projects in combating the virus. - Their existing iMedic adds value to the Sputnik V mass deployment. Management plans to make available to everyone who is going to be vaccinated with Sputnik V to have free access to the iMedic platform to track the symptoms or side effects. These will improve post-vaccination tracking and healthcare monitoring in the future. 9) SUMMARY MOU seems to indicate that UCREST would have an additional of revenue and earnings, under zero to minimal cost. ❗️However, MOU may or may not materialise. What will be the final outcome? Time will tell. DISCLAIMER Information is compiled from publicly available resources. Also, we are merely attempting to connect the dots, not predicting the future. Our understanding could be inaccurate. Valuation of UCREST stock is beyond scope. There is no BUY/SELL recommendation. Investors own their investment decisions and outcomes. 17/04/2021 9:18 PM kytan On 16th night sharing, more info still not expose on above part 1 and part 2 17/04/2021 9:20 PM kytan When managing director share the info, i feel comfortable to hold. Especially curent ucrest core business also making profit, better than Solution. 17/04/2021 9:23 PM kytan Hopefully the Boss will do another investor briering after Q result out end Apr to update us latest vaccine MOU progress 17/04/2021 9:25 PM fengpinglangjin Mr Ed mentioned that rdif is in the process of transfer fech to the 3 shortlisted manufactuer out of 10. Ucrest already secured 600m capacity from china plant. 2 other manufacturer will fill up the remianing 400m. Mr Eg also states current MOU is already enough for the execution of the project. The nex agrrement will be the sales agreement when delivery is due. Ie. All things are already rolling. The shortlisting is completed. Tech is transfering. The mou is binding now. 17/04/2021 9:47 PM fengpinglangjin all these are mentioned in live. Those din c the live will not know. The mou got far mor details which are confidential. Which are not disclosable.probably including the margin and more confidential details. Thqt why Mr Eg is able to giv a rough margin of profit projection in the live. 17/04/2021 9:49 PM Alfonso The news like godlike power to bring this stock to a firm ground of unbreakable RM1. Seems like next week going to limit up again. So syioknya. 17/04/2021 11:36 PM  | |
